Summary. Three hundred and fifty pregnancies were monitored by transabdominal amniocentesis in the fourteenth to sixteenth week of gestation followed by karyotyping or The safety and reliability of amniocentesis and the possible effects on the outcome of pregnancy are evaluated. Prenatal diagnosis offers a promising alternative for parents who are at risk of having a child with a genetic disease which can be detected in amniotic fluid or in cultured amniotic fluid cells.
(4 to 8 weeks). The development of microchemical techniques enabled enzyme assays on small numbers of cultured amniotic fluid cells and a reduction in the time required for parental diagnosis (Galjaard et al, 1973; 1974c; 1974d; Wendel et al, 1973) .
A recent and important contribution to prenatal diagnosis was the finding by Brock and Sutcliffe (1972) , that the alpha-fetoprotein level in amniotic fluid is increased when the fetus has an open defect of the neural tube. When relatively new techniques like those of prenatal diagnosis are used full assessment of the scope and risks of the various procedures is possible only when sufficiently large series of diagnoses for different groups of genetic diseases can be analysed, including follow-up studies on children after amniocentesis. The present report describes 350 prenatal diagnoses performed in pregnancies at risk for a chromosomal aberration, X-linked disease, neural tube defect, or 1 of 11 different metabolic diseases.
Methods and materials
Clinical methods. The actual genetic risk was estimated in each woman referred for prenatal diagnosis TAB PREGNANCIES MONITORED BY AN by taking the family history. Additional diagnostic tests on previous affected children, parents, or relatives (karyotyping, enzymatic studies, etc.) were performed when necessary in order to make sure that amniocentesis was justified. A risk higher than 1% for a disease amenable to prenatal diagnosis was taken as an indication for amniocentesis (Table I) . The indication for advanced matemal age was accordingly limited to women 38 years and older.
The procedure of amniocentesis and its related risks were explained to the patients.
Transabdominal amniocentesis (Queenan, 1970) was performed under local anaesthesia in the fourteenth to sixteenth week after the last menstrual period. Ultrasound examination was carried out to localize the placenta, measure the fetal biparietal diameter, estimate the volume of amniotic fluid, and exclude the presence of twins. Amniotic fluid, 10 to 15 ml, was aspirated into a siliconized glass syringe.
Selective abortion was performed when indicated by intra-amniotic injection of hypertonic saline or by intra- or analyses were performed by our own group. Samples referred by other centres were transported in siliconized glass flasks. Amniotic fluid samples from normal pregnancies were kindly provided by Dr K. L. Garver, Magee Women's Hospital, Pittsburgh (USA) and stored until use as controls in biochemical studies, according to a procedure described earlier .
Cell culture methods for amniotic fluid cells. After counting the cells with a haemocytometer the amniotic fluid was centrifuged for 5 minutes at 80 x g and the supernatant was centrifuged for another 10 minutes at 1500 xg and stored at -70°C until needed. The collected cells were cultured according to different techniques, especially during the initial phase of this study. The procedure used in the last 300 cases is described here.
The cell pellets were resuspended in Ham's F10 medium supplemented with 25% v/v of fetal calf serum (Flow Company), penicillin (50 U/ml), and streptomycin (50 ug/ml). For chromosome analysis cells were seeded on 22 x 22 mm coverslips in different 35 mm Falcon plastic Petri dishes. Aliquots of 0.75 ml, containing 50 000-100 000 cells, were gently pipetted on the top of the coverslips and left overnight in a fully humidified incubator with 5 % CO2 in air as the gaseous phase before additional medium was added up to 2 ml. The medium was changed after 5 days and subsequently every second day until sufficient mitotic cells for harvesting were present. Some bloody samples of amniotic fluid were processed according to Lee, Gregson, and Walker (1970) ; as this did not give significant improvement in cell growth, the method was omitted.
Culture methods for biochemical analysis were similar. Cells cultured in the Petri dishes were used to provide cell homogenates. In addition cells were seeded in Mylar dishes with a thin plastic bottom to enable microchemical studies on groups of 100 to 300 dissected cells (Galjaard et al, 1973; 1947c) . For each prenatal diagnosis amniotic fluid cell samples from a comparable gestational period cultivated under similar conditions (medium, pH, cell number seeded, period of cell cultivation after subcultures) were used as controls.
Amniotic fluid cell cultures received from outside centres were grown in Ham's FIO medium for at least 24 hours before harvesting.
Chromosome analysis of cultured amniotic fluid cells. When sufficient mitotic cells were observed in a culture, colchicine (0.02 jug/ml) was added to the medium for 3.5 to 4 hours. A procedure adapted from P. Hosli (1970, personal communication) was used for in situ spreading and gradual fixation to avoid loss of mitotic cells. Q banding was performed with a 0.5% solution of atebrin (Caspersson, Lomakka, and Zech, 1971) . Metaphases were studied with a Leitz fluorescence microscope equipped with a vertical illuminator and filter combinations as described by Van der Ploeg and Ploem (1973) .
A minimum of 16 metaphases was analysed from at least two different cultures and a minimum of 3 metaphases was karyotyped (Paris Conference, 1971) . Polyploid metaphases were not included. A complete fetal chromosome analysis was used for prenatal sex determination in pregnancies at risk for an X-linked disease. Microchemical analysis of cultured amniotic fluid cells. Cell homogenates or dissected groups of 100 to 300 freeze-dried cultured cells were prepared as described (Galjaard et al, 1973; 1974c) . The procedures for the microchemical assay of a-galactosidase (Galjaard et al, 1974d) , acid a-1,4-glucosidase (Galjaard et al, 1973) , acid ,-galactosidase (Galjaard et al, 1974a) , fi-D-N-acetylglucosaminidase (Galjaard et al, 1974b) and arysulphatase A (Niermeijer et al, 1974) have been described. a-L-iduronidase was measured according to Hall and Neufeld (1973) using a final volume of 30 ul. ,-glucosidase was assayed using a procedure modified from Beutler et al (1971) .
Electrophoresis of ,-D-N-acetylglucosaminidase was performed as described (Galjaard et al, 1974b) and heat inactivation studies of ,-D-N-acetylglucosaminidase isoenzymes in amniotic fluid supernatant were performed according to O'Brien et al (1970) .
The results of assays on cell homogenates were expressed per mg protein as determined according to Lowry et al (1951) Prenatal diagnosis of metabolic diseases. Thirty-four pregnancies were monitored for 11 different metabolic diseases (Table I) . Some of these results have been presented in detail elsewhere (Niermeijer et al, 1974 (Niermeijer et al, , 1975 Galjaard et al, 1974d) .
The diagnosis in a previously affected child was made according to the methods listed in Table III and it is apparent that the enzyme defect had been identified in the majority of cases by studies on leucocytes and fibroblasts. When only necropsy studies were available, the parents were informed that prenatal diagnosis in their cases had certain restrictions.
In the first two pregnancies tested for Pompe's disease insufficient cell growth was obtained and the activity of acid a-1,4-glucosidase in the amniotic fluid supernatant was normal. At that time (1969) such a test was still considered as reliable (Nadler and Messina, 1969) . Unfortunately, one of these children proved to be affected with Pompe's disease. In all 11 subsequent cases prenatal diagnosis was based on assays on cultured cells. In two cases very low activities of acid a--1,4-glucosidase were observed; after interruption of these pregnancies in the eighteenth week enzyme assays on fetal tissues (liver, muscle, heart, brain, and kidney) confirmed the diagnosis. In one instance a low activity of acid a--1,4-glucosidase in an early primary amniotic fluid cell culture was erroneously interpreted as compatible with Pompe's disease in the fetus, and the pregnancy was terminated. Three amniotic fluid cell cultures were monitored for Sandhoff's disease and all showed the presence of both hexosaminidase A and B by electrophoresis and a normal total hexosaminidase activity. One of these children has been born and has serum hexosaminidase activity in the normal range.
Microchemical assays of /3-galactosidase were performed on dissected groups of 10 to 20 freezedried cultured cells from two pregnancies at risk for GM,-gangliosidosis. The diagnoses were completed 9 and 15 days after amniocentesis and showed normal values (Table IV) the factor 1 mg protein=3. 106 cells (Galjaard et al, 1974c) . Microchemical analyses were also done on freezedried cells cultured from a pregnancy at risk for Fabry's disease. The result was available 11 days after amniocentesis. Cell homogenates from replicate cultures were also analysed, both in our laboratory and in the Institute of Medical Genetics, Copenhagen. Normal a-galactosidase activities and a normal male karyotype were found. A normal boy was born (Galjaard et al, 1974d) .
In three cases at risk for Hurler's disease 35S04-incorporation and chase studies suggested normal mucopolysaccharide metabolism in the fetus. In one case, however, a-L-iduronidase activity fell in the same range found in fibroblasts from Hurler patients. According to the suggestion by Hall and Neufeld (1973) A fl-glucosidase activity half of control amniotic fluid sample but clearly higher than that found in a previous pregnancy was found in cultured amniotic fluid cells from a pregnancy at risk for Gaucher's disease. The assay of branched-chain ketoacid decarboxylase activity was completed 11 days after amniocentesis in a pregnancy at risk for maple syrup urine disease. Normal activity was found.
In children born after prenatal testing for metabolic defects, biochemical assays on leucocytes or fibroblasts were performed whenever possible and in 15 cases confirmation of the prenatal diagnosis was obtained. The other pregnancies were not completed when this report was written.
Prenatal diagnosis of neural tube defects. a-fetoprotein levels (AFP) were raised (90 ,ug/ml in week 27; 13 in week 29 and 90 in week 22, respectively) in 3 of 19 cases where hydramnios developed in the second half of pregnancy. Ultrasound examination showed anencephalic fetuses in these three cases. No abnormal raised levels were found in 28 pregnancies tested for the recurrence risk of a neural tube defect.
In a pregnancy tested for the recurrence risk of trisomy 21 during the sixteenth week an AFP level of 70 ,ug/ml was found; this sample, however, showed admixture with fetal red blood cells and a second sample obtained at the nineteenth week of the pregnancy showed a normal AFP level. 
Discussion
Evaluation of amniocentesis and amniotic fluid cell culture. Prenatal diagnosis may be evaluated according to several different criteria. The risk of amniocentesis to the mother may be estimated as negligible; the risk to the fetus as measured by the rate of spontaneous abortion after amniocentesis differs from one study to the other: 1: 155 (Nadler and Gerbie, 1970) , 4:73 (Doran et al, 1974) , 3:100 , 1:50 (Prescott et al, 1973) , 10:128 (Robinson et al, 1973) , and 7:477 (Milunsky and Atkins, 1974) . These variations may be caused by differences in techniques and by different criteria during the follow-up period. For an abortion to be caused by amniocentesis, a time relation between these two events should exist (Wahlstrbm, Bartsch, and Lundberg, 1974) . For the period of one month after amniocentesis 3 spontaneous abortions occurred in our series of 350 pregnancies (about 1%); in one of these amniocentesis was clearly the cause of the fetal loss. The average risk of about 100 is not significantly different from the risk of spontaneous abortion in the second trimester, which was estimated in the U.S.A. as 1.2% (Javert, 1957; Shapiro, Jones, and Densen, 1962) and as 1 to 300 in Sweden (Petterson, 1968) . Of the total fetal loss, 3200 occurred between 12 and 19 weeks of gestation, and 12% at 20 weeks or more in a study on spontaneous abortion (Shapiro et al, 1962) .
Follow-up studies on the children born after prenatal diagnosis failed to detect either an increase in congenital malformations or a specific malformation pattern associated with the puncture. Hsu and Hirschhorn (1974) , Golbus et al (1974) , and Allen et al (1974) observed similar results.
We failed to obtain amniotic fluid at the first amniocentesis in 400 of the cases in the present series; failure rates of 1% (Nadler and Gerbie, 1970) , 6% Prescott et al, 1973; Robinson et al, 1973; Wahlstrom, Bartsch, and Lundberg, 1974) , 8.5% (Doran et al, 1974) , and 10% (Milunsky and Atkins, 1974) have been reported. The failure rate of amniotic fluid cell culture in the present study is 1%; others reported either similar data (Nadler and Gerbie, 1970) or higher figures: 10% (Milunsky and Atkins, 1974; Allen et al, 1974) and 300o (Robinson et al, 1973) .
The length of the waiting period between amniocentesis (in the fourteenth to sixteenth week) and the eventual diagnosis is another criterion for evaluating prenatal diagnosis. This period should not exceed 2 to 3 weeks so that if necessary abortion can be performed before the mother experiences fetal movements (Ferguson-Smith et al, 1971; Golbus et al, 1974) . In the present study the result of prenatal chromosome analysis was available within 3 weeks in 87% of the cases (47%/ of the parents knew the result within 2 weeks). These data are similar to those from Nadler and Gerbie (1970), Therkelsen et al (1972) and Milunsky and Atkins (1974) ; Prescott et al (1973) and Golbus et al (1974) used longer periodls.
Indications and problems in prenatal chromosome analysis. Prenatal monitoring has become a routine for pregnancies at advanced maternal age and for cases with a recurrence risk of trisomy 21 (Down's syndrome). The recurrence risk of trisomy 21 was found to be 1% in a series of prenatal diagnoses collected by Milunsky (1973) and a similar risk was observed in the present series. In the group of pregnancies at advanced maternal age the risk for chromosomal aberrations (determined from several series of prenatal diagnosis) is 1.5% in mothers between 35 and 39 years and about 3%/ in the group of 40 years and older (Hsu and Hirschhorn, 1974) . In the present series 4 nondisjunctions were found in 68 pregnancies in mothers 40 years and older. These risk figures are higher than those generally given in genetic counselling to older mothers. The risk for a child with a chromosomal aberration is much higher when one of the parents is a carrier of a balanced translocation (Table II) . After the detection of the familial nature of a translocation in a family with one child affected with Down's syndrome (Table II , Case 1), several relatives were karyotyped. In this way another high-risk pregnancy was identified in time to give the parents the chance of requesting prenatal diagnosis (Table II , Case 5). Timely identification of translocation carriers is one of the important tasks of a genetic counselling service.
A number of the technical problems in chromosome analysis on cultured amniotic fluid cells has been discussed recently, including chromosomal mosaicism (Kardon et al, 1972; Hsu et al, 1973; Cox et al, 1974) and structural aberrations arising in vitro by contamination with mycoplasma . One case of a 45,XO/46,XY mosaicism in the present study is comparable with the observation of Kardon et al (1972) and this mosaicism probably arose in vitro; however, cytogenetic studies on the fetus were not possible. In one case inconsistent structural aberrations were detected; metaphases from a repeat culture (obtained after a second amniocentesis) were normal. The role of mycoplasma in this series is difficult to evaluate. Though all tests were negative, mycoplasma testing was performed only periodically. Nadler (1972) (Boue and Boue, 1973) . In sporadic balanced reciprocal translocations, which occur in about 1 of every 3000 newborns , small deletions, not discernible with present techniques, or a position effect may be present (Skovby and Niebuhr, 1974) . In addition, de novo balanced structural autosomal rearrangements might be associated or the cause of severe mental retardation (Jacobs, 1974 An XYY karyotype may be expected in 0.09% of newborns, an XXY in 0.1% .
Even after extensive studies on the clinical aspects of the XYY genotype (see for reviews : Hook, 1973; Borgaonkar and Shah, 1974) Prenatal diagnosis of metabolic disease. The prenatal diagnosis of metabolic defects formerly required a period of 4 to 8 weeks after amniocentesis and parents had to be warned about waiting periods of up to 6 weeks, when prenatal diagnosis was discussed (Milunsky, Atkins, and Littlefield, 1972 (Niermeijer et al, 1975) , for Fabry's disease in 11 days (Galjaard et al, 1974d ) and for GM,-gangliosidosis in 9 and 12 days. In previous reports on prenatal diagnosis of GM,-gangliosidosis the result became available after 18 days (Lowden et al, 1973) and 4 weeks (Kaback et al, 1973; Booth, Gerbie, and Nadler, 1973) . The prenatal monitoring for metachromatic leucodystrophy has required 3 to 4 weeks (Leroy et al, 1973; Van der Hagen et al, 1973) ; in the present study diagnosis was performed in 16 and 18 days in two pregnancies studied. A further reduction in this waiting period may be achieved by decreasing the final volume of the enzymatic reaction to 1 to 5,u and measuring the extinction in a microspectrophotometer (Galjaard et al, 1974c) . Testing for maple syrup urine disease using a radioactive substrate was completed in 11 days in this study; others have used periods of up to 8 weeks (Elsas et al, 1974; Hoo, Latta, and Schaumloffel, 1974) . Using the methods described, the interval between amniocentesis and diagnosis for a number of metabolic diseases is comparable to the period required for prenatal chromosome analysis.
The basic requirements for reliable prenatal diagnosis of metabolic diseases were reviewed by Littlefield (1971) , Burton et al (1974) and Hsu and Hirschhorn(1974) . The present experience indicates that the following points should be considered:
1. The expression of the metabolic defect should be characterized in fibroblasts from a previous affected child or relative from the family under study, and the level of residual enzymatic activity should be studied, since genetic heterogeneity exists within apparently identical metabolic diseases. From Table III one may note, that these data were not available in all cases studied. Many parents will not seek genetic counselling until after the death of an affected child; fibroblast cultures from affected children can be stored in a cell bank to provide control material for a future prenatal diagnosis.
2. A number of variables may influence enzymatic activities in cultured cells and sufficient experience with these factors is essential. The type of tissue culture media (Ryan, Lee, and Nadler, 1972; Butterworth et al, 1974) , its pH (Eagle, 1973; Lie et al, 1973) , differences in cell types in amniotic fluid cell cultures (Gerbie et al, 1972) , and the effect of growth to confluency (Okada et al, 1971; Russell, Russell, and Littlefield, 1972; Butterworth et al, 1973; Galjaard et al, 1974e ) may all effect enzymatic activities. The activity of some lysosomal hydrolases may show considerable variations in primary cultures of amniotic fluid cells; in later subcultures the activities increased during prolonged cultivation (Niermeijer et al, 1975) . Amniotic fluid cell cultures used as controls in prenatal diagnosis should, therefore, be carefully matched for their growth stage and passage. Since fibroblast cultures and amniotic fluid cultures have important enzymatic differences, fibroblasts should not be used as the sole controls (Kaback, Leonard, and Parmley, 1971) .
Prenatal diagnosis of neural tube defects. The prenatal diagnosis of open tube defects by raised levels of a-fetoprotein in the amniotic fluid (Brock and Sutcliffe, 1972) offers new perspectives in genetic counselling. The risk of open neural tube defects will become a common indication for prenatal diagnosis, since neural tube defects and Down's syndrome have a comparable frequency. Closed lesions or smaller open defects possibly remain undetectable by AFP levels, and the parents should be so informed; however, the clinical effects of these lesions may be milder in some cases (Laurence et al, 1973; Harris et al, 1974) . The reliability of the method has been proven in different centres (Allan et al, 1973; Milunsky and Alpert, 1974; Brock, Scrimgeour, and Nelson, 1975) . Aspecific rises in second trimester amniotic fluids may be caused by admixture with fetal blood, which has a high AFP concentration (Field et al, 1974; Ward and Stewart 1974) . In the case observed in this study the amniotic fluid AFP level returned to normal levels in 10 days. In our laboratory blood-stained amniotic fluids were tested for fetal Hb in cases with a recurrence risk for neural tube defects.
In our series of 350 pregnancies, selective abortion was performed as a result of the prenatal diagnosis in 36 cases. In 90%o of the cases the pregnancies were continued knowing that the risk of a particular genetic disease was eliminated. Ferguson-Smith (1974) 4. Prenatal diagnosis of metabolic disorders should be carried out only in centres that have sufficient experience with biochemical analysis of cultured human cells. Experience with the biochemistry of the metabolic diseases studied is a prerequisite as is the availability of the proper control material in a cell bank. Microchemical techniques have the advantage of reducing the waiting periods for the parents and should be available in the diagnostic centre.
Collaboration between different centres is required because of the relative infrequency of most metabolic diseases and the facilities and know-how required.
